173 References Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med (2020) 383(27):2652-2664. doi: 10.1056/NEJMra2002697. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet (2010) 42(12):1118-25. doi: 10.1038/ng.717. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol (2017) 14(12):739-749. doi: 10.1038/nrgastro.2017.110. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol (2019) 4(2):293-305. doi: 10.1038/s41564-018-0306-4. Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med (2018) 10(472):eaap8914. doi: 10.1126/scitranslmed.aap8914. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 104(34):13780-5. doi: 10.1073/pnas.0706625104. Li H, Limenitakis JP, Greiff V, Yilmaz B, Schären O, Urbaniak C, et al. Mucosal or systemic microbiota exposures shape the B cell repertoire. Nature (2020) 584(7820):274-8. doi: 10.1038/s41586-020-2564-6. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol (2014) 14:189. doi: 10.1186/s12876014-0189-7. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis (2011) 17(1):362-81. doi: 10.1002/ibd.21403. Christmann BS, Abrahamsson TR, Bernstein CN, Duck LW, Mannon PJ, Berg G, et al. Human seroreactivity to gut microbiota antigens. J Allergy Clin Immunol (2015) 136(5):1378-86.e1-5. doi: 10.1016/j. jaci.2015.03.036. Alexander KT, Zhao Q, Reif M, Rosenberg AF, Mannon PJ, Duck LW, et al. Human Microbiota Flagellins Drive Adaptive Immune Responses in Crohn’s Disease. Gastroenterology (2021) 161(2):522-535.e6. doi: 10.1053/j.gastro.2021.03.064. Monteleone G, Peluso I, Fina D, Caruso R, Andrei F, Tosti C, et al. Bacteria and mucosal immunity. Dig Liver Dis (2006) 38 Suppl 2:S256-60. doi: 10.1016/S1590-8658(07)60005-X. Harmsen HJM, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn’s disease patients have more IgG-binding fecal bacteria than controls. Clin Vaccine Immunol (2012) 19(4):515-21. doi: 10.1128/CVI.05517-11. van der Waaij LA, Kroese FGM, Visser A, Nelis GF, Westerveld BD, Jansen PLM, et al. Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur J Gastroenterol Hepatol (2004) 16(7):66974. doi: 10.1097/01.meg.0000108346.41221.19. Masu Y, Kanazawa Y, Kakuta Y, Shimoyama Y, Onodera M, Naito T, et al. Immunoglobulin subtypecoated bacteria are correlated with the disease activity of inflammatory bowel disease. Sci Rep (2021) 11(1):16672. doi: 10.1038/s41598-021-96289-5. Spekhorst LM, Imhann F, Festen EAM, van Bodegraven AA, de Boer NKH, Bouma G, et al. Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. BMJ Open (2017) 7(11):e016695. doi: 10.1136/bmjopen-2017-016695. Heida FH, van Zoonen AGJF, Hulscher JBF, Te Kiefte BJC, Wessels R, Kooi EMW, et al. A Necrotizing Enterocolitis-Associated Gut Microbiota Is Present in the Meconium: Results of a Prospective Study. Clin Infect Dis (2016) 62(7):863-870. doi: 10.1093/cid/ciw016. Antimicrobial IgG immune responses in IBD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
RkJQdWJsaXNoZXIy MjY0ODMw